Trials / Approved For Marketing
Approved For MarketingNCT03843892
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Expanded Access Use of OFEV (Nintedanib) in Non-IPF Interstitial Lung Disease
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OFEV | twice daily |
Timeline
- First posted
- 2019-02-18
- Last updated
- 2024-12-10
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03843892. Inclusion in this directory is not an endorsement.